Michael Jung, Distinguished Professor of Chemistry and Biochemistry at UCLA, has been selected to receive the 2015 Team Science Award from the American Association for Cancer Research. The award recognizes prominent researchers for innovative work in the detection, diagnosis, prevention and treatment of cancer. Jung will receive the award at the association's annual meeting in Philadelphia on April 19.
Jung worked with Drs. Charles Sawyers and Howard Scher of the Memorial Sloan Kettering Cancer Center to develop the anti-androgen drug enzalutamide (Xtandi), which has been found effective in slowing or stopping the progression of prostate cancer for several months and received FDA approval in 2012.
Jung earned his Ph.D. at Columbia University and did post-doctoral research in Zurich before joining the faculty of UCLA, where he has taught for more than 40 years. In addition to his role in the department of chemistry and biochemistry, he is director of the David Geffen School of Medicine Bioscience Synthetic Chemistry Core and a member of the California NanoSystems Institute.
